Relative Copy Number Gain of MYC in Diagnostic Needle Biopsies is an Independent Prognostic Factor for Prostate Cancer Patients

European Urology

Volumn 52, Issue 1, 2007, Pages 116-125

  Ribeiro, Franclim R ^a   Henrique, Rui ^a,b   Martins, Ana T ^a   Jerónimo, Carmen ^a,c   Teixeira, Manuel R ^a,b  

^a PORTUGUESE ONCOLOGY INSTITUTE   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

^c UNIVERSIDADE FERNANDO PESSOA   (Portugal)

Author keywords

Fluorescent in situ hybridization; Molecular cytogenetics; Prognostic marker; Prostate cancer; Sextant biopsies

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; ASPIRATION BIOPSY; CANCER SURVIVAL; CHROMOSOME 18; CLINICAL PRACTICE; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; DNA FLANKING REGION; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; ONCOGENE MYC; PRIORITY JOURNAL; PROGNOSIS; PROSTATE BIOPSY; PROSTATE CANCER;

AGED; AGED, 80 AND OVER; BIOPSY, FINE-NEEDLE; CHROMOSOMES, HUMAN, PAIR 18; CHROMOSOMES, HUMAN, PAIR 8; DNA PROBES; FEASIBILITY STUDIES; FOLLOW-UP STUDIES; GENE DOSAGE; GENES, MYC; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; NEOPLASM STAGING; PORTUGAL; PROGNOSIS; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 34249039594     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2006.09.018     Document Type: Article

References (34)

1. Rose M.G., Degar B.A., and Berliner N. Molecular diagnostics of malignant disorders. Clin Adv Hematol Oncol 2 (2004) 650-660
2. Van Dekken H., Rosenberg C., Krijtenburg P.J., and Alers J.C. Interphase cytogenetics and comparative genomic hybridization of human epithelial cancers and precursor lesions. Histochem Cell Biol 108 (1997) 419-430
3. Karan D., Lin M.F., Johansson S.L., and Batra S.K. Current status of the molecular genetics of human prostatic adenocarcinomas. Int J Cancer 103 (2003) 285-293
4. Nupponen N.N., and Visakorpi T. Molecular cytogenetics of prostate cancer. Microsc Res Tech 51 (2000) 456-463
5. DeMarzo A.M., Nelson W.G., Isaacs W.B., and Epstein J.I. Pathological and molecular aspects of prostate cancer. Lancet 361 (2003) 955-964
6. Henke R.P., Krüger E., Ayhan N., Hübner D., and Hammerer P. Frequency and distribution of numerical chromosomal aberrations in prostatic cancer. Hum Pathol 25 (1994) 476-484
7. Takahashi S., Qian J., Brown J.A., et al. Potential markers of prostate cancer aggressiveness detected by fluorescence in situ hybridization in needle biopsies. Cancer Res 54 (1994) 3574-3579
8. Visakorpi T., Hyytinen E., Kallioniemi A., Isola J., and Kallioniemi O.P. Sensitive detection of chromosome copy number aberrations in prostate cancer by fluorescence in situ hybridization. Am J Pathol 145 (1994) 624-630
9. Persons D.L., Gibney D.J., Katzmann J.A., Lieber M.M., Farrow G.M., and Jenkins R.B. Use of fluorescent in situ hybridization for deoxyribonucleic acid ploidy analysis of prostatic adenocarcinoma. J Urol 150 (1993) 120-125
10. Brown J.A., Alcaraz A., Takahashi S., Persons D.L., Lieber M.M., and Jenkins R.B. Chromosomal aneusomies detected by fluorescent in situ hybridization analysis in clinically localized prostate carcinoma. J Urol 152 (1994) 1157-1162
11. Zitzelsberger H., Szucs S., Weier H.U., et al. Numerical abnormalities of chromosome 7 in human prostate cancer detected by fluorescence in situ hybridization (FISH) on paraffin-embedded tissue sections with centromere-specific DNA probes. J Pathol 172 (1994) 325-335
12. Qian J., Bostwick D.G., Takahashi S., et al. Chromosomal anomalies in prostatic intraepithelial neoplasia and carcinoma detected by fluorescence in situ hybridization. Cancer Res 55 (1995) 5408-5414
13. Kallioniemi O.P., Kallioniemi A., Piper J., et al. Optimizing comparative genomic hybridization for analysis of DNA sequence copy number changes in solid tumors. Genes Chromosomes Cancer 10 (1994) 231-243
14. Fu W., Bubendorf L., Willi N., et al. Genetic changes in clinically organ-confined prostate cancer by comparative genomic hybridization. Urology 56 (2000) 880-885
15. Alers J.C., Rochat J., Krijtenburg P.J., et al. Identification of genetic markers for prostatic cancer progression. Lab Invest 80 (2000) 931-942
16. Ribeiro F.R., Diep C.B., Jeronimo C., et al. Statistical dissection of genetic pathways involved in prostate carcinogenesis. Genes Chromosomes Cancer 45 (2006) 154-163
17. Alers J.C., Krijtenburg P.J., Vis A.N., et al. Molecular cytogenetic analysis of prostatic adenocarcinomas from screening studies: early cancers may contain aggressive genetic features. Am J Pathol 158 (2001) 399-406
18. Steiner T., Junker K., Burkhardt F., Braunsdorf A., Janitzky V., and Schubert J. Gain in chromosome 8q correlates with early progression in hormonal treated prostate cancer. Eur Urol 41 (2002) 167-171
19. Van Dekken H., Alers J.C., Damen I.A., et al. Genetic evaluation of localized prostate cancer in a cohort of forty patients: gain of distal 8q discriminates between progressors and nonprogressors. Lab Invest 83 (2003) 789-796
20. Teixeira M.R., Ribeiro F.R., Eknaes M., et al. Genomic analysis of prostate carcinoma specimens obtained via ultrasound-guided needle biopsy may be of use in preoperative decision-making. Cancer 101 (2004) 1786-1793
21. Aus G., Abbou C.C., Bolla M., et al. EAU guidelines on prostate cancer. Eur Urol 48 (2005) 546-551
22. Ribeiro F.R., Jeronimo C., Henrique R., et al. 8q gain is an independent predictor of poor survival in diagnostic needle biopsies from prostate cancer suspects. Clin Cancer Res 12 (2006) 3961-3970
23. Gleason D.F., and Mellinger G.T. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol 111 (1974) 58-64
24. In: Sobin L.H., and Wittekind C. (Eds). TNM classification of malignant tumours. 6th ed. (2002), Wiley-Liss, New York
25. Jenkins R.B., Qian J., Lieber M.M., and Bostwick D.G. Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization. Cancer Res 57 (1997) 524-531
26. Boxer L.M., and Dang C.V. Translocations involving c-myc and c-myc function. Oncogene 20 (2001) 5595-5610
27. Bubendorf L., Kononen J., Koivisto P., et al. Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays. Cancer Res 59 (1999) 803-806
28. Tsuchiya N., Slezak J.M., Lieber M.M., Bergstralh E.J., and Jenkins R.B. Clinical significance of alterations of chromosome 8 detected by fluorescence in situ hybridization analysis in pathologic organ-confined prostate cancer. Genes Chromosomes Cancer 34 (2002) 363-371
29. Qian J., Hirasawa K., Bostwick D.G., et al. Loss of p53 and c-myc overrepresentation in stage T(2-3)N(1-3)M(0) prostate cancer are potential markers for cancer progression. Mod Pathol 15 (2002) 35-44
30. Sato K., Qian J., Slezak J.M., et al. Clinical significance of alterations of chromosome 8 in high-grade, advanced, nonmetastatic prostate carcinoma. J Natl Cancer Inst 91 (1999) 1574-1580
31. Henke R.P., Hammerer P., Graefen M., et al. Interphase cytogenetic study of preoperative core biopsies for the prediction of early serum prostate specific antigen recurrence after radical prostatectomy of clinically localized prostate carcinoma. Cancer 83 (1998) 977-988
32. Al Maghrabi J., Vorobyova L., Toi A., Chapman W., Zielenska M., and Squire J.A. Identification of numerical chromosomal changes detected by interphase fluorescence in situ hybridization in high-grade prostate intraepithelial neoplasia as a predictor of carcinoma. Arch Pathol Lab Med 126 (2002) 165-169
33. Bastacky S., Cieply K., Sherer C., Dhir R., and Epstein J.I. Use of interphase fluorescence in situ hybridization in prostate needle biopsy specimens with isolated high-grade prostatic intraepithelial neoplasia as a predictor of prostate adenocarcinoma on follow-up biopsy. Hum Pathol 35 (2004) 281-289
34. Humphrey P.A. Gleason grading and prognostic factors in carcinoma of the prostate. Mod Pathol 17 (2004) 292-306